Cerrion Raises $18M In Series A Funding Led By Creandum For AI Video Agent Platform

Cerrion, a Zurich-based provider of an AI video agent platform for real-time production line monitoring, raised $18M in Series A funding led by Creandum with participation from existing backers and notable angels. Founded in 2021 by Karim Saleh and Nikolay Kobyshev, the company plans to use the capital to double its teams in Europe and the U.S. and expand its platform beyond vision to support a wider range of manufacturing processes. Cerrion’s technology is already deployed across three continents and in live production environments at manufacturers such as Unilever, Riedel, and Schott Zwiesel, helping identify and resolve issues for brands like Pepsi, Coca-Cola, Pfizer, and Novartis. FOUNDERS: Karim Saleh & Nikolay Kobyshev INVESTORS: Creandum, Y Combinator, Goat Capital, 10x Founders, Session VC, Harry Stebbings, Oskar Hjertonsson, Thomas Wolf, Garret Langley, Filip Kaliszan, Marc Maurer & Carl Rivera ROUND: Series A AMOUNT: $18,000,000 HQ: #Zürich #Switzerland #VentureCapital #Cerrion #KarimSaleh #NikolayKobyshev #Creandum #YCombinator #GoatCapital #10xFounders #SessionVC #HarryStebbings #OskarHjertonsson #ThomasWolf #GarretLangley #FilipKaliszan #MarcMaurer #CarlRivera #TradedVC

More Deals

View All

Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts. FOUNDERS: Ben Lamm & George Church TARGET VALUATION: $23,000,000,000 HQ: Dallas, Texas #VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC